July earnings matter, but long-term growth matters more.
Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products, and its portfolio boasts dozens of patented devices that generate consistent ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Tehuan Harris is a news and features journalist at Collider, reporting and writing about all things music and reality TV (sometimes). She is a talented journalist and a natural storyteller who writes ...
Abbott must pay $495M in damages after girl develops dangerous disease from premature infant formula
A jury found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Organic sales growth for the underlying ...
Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...
Abbott Laboratories on Thursday announced its over-the-counter continuous glucose monitor Lingo is available in the U.S. Lingo can be purchased without a prescription, and it's intended for adults who ...
Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results